Optimum screening cut-offs for HbA1c in emergency setting similar to outpatient care….
Read More »Managing Clinical Problems in Diabetes, Case Study #13: Gestational Diabetes
Edited by Trisha Dunning AM, RN, MEd, PhD, CDE, FRCNA and Glenn Ward MBBS, BSc, DPhil (Oxon), FRACP, FRCPath Mrs. ORA was referred to a diabetes educator when she developed diabetes at 29.5 weeks’ gestation. Mrs. ORA is a 30-year-old primigravida and is 29.5 weeks pregnant. She was referred to the …
Read More »NIH Findings Have Potential to Curb Obesity and Type 2 Diabetes
Discovery makes white fat mimic energy-burning brown fat, muscle.…
Read More »ADA: Safety and Efficacy of Once-Monthly Exenatide over 20 Weeks in Patients with Type 2 Diabetes
Exenatide, a GLP-1 receptor agonist, improves glycemic control and body weight with twice daily or once weekly subcutaneous (SC) injections in patients with type 2 diabetes (T2DM)….
Read More »ADA: Linagliptin Has Similar Efficacy to Glimepiride but Improved Cardiovascular Safety over 2 Years in Patients with Type 2 Diabetes Inadequately Controlled on Metformin
Type 2 diabetes mellitus (T2DM) often requires combination therapy to maintain glycemic control. Adding a sulfonylurea to metformin therapy improves glycemic control, but can cause hypoglycemia and weight gain. This 2-yr double-blind trial investigated the long-term efficacy and safety of adding linagliptin or glimepiride to ongoing metformin to treat T2DM….
Read More »ADA: Exenatide/Diet vs. Diet Alone for Treatment of Prediabetes
Exenatide yields beta cell improvement and weight loss in individuals with diabetes but has not been well-studied in individuals with prediabetes….
Read More »ADA: Efficacy and Safety of Lixisenatide Once-Daily vs. Exenatide Twice-Daily in Type 2 DM Inadequately Controlled on Metformin (GetGoal-X)
This randomized, open-label, parallel-group, multicenter, 24-wk main treatment study, followed by a variable extension of at least 52 wk, compared the efficacy and safety of lixisenatide 20 µg QD and exenatide 10 µg BID in 634 T2DM patients insufficiently controlled on metformin ≥1.5 g/day (mean age 57.4 yr, diabetes duration …
Read More »ADA: CV Risk with Linagliptin in Patients with Type 2 Diabetes: A Pre-Specified, Prospective, and Adjudicated Meta-Analysis from a Large Phase III Program
The cardiovascular (CV) benefit of glucose lowering, particularly if too intensive, in type 2 diabetes mellitus (T2DM) is currently debated. Some modalities have even been reported, unexpectedly, to be associated with worse CV outcomes. To investigate the CV profile of the novel DPP-4 inhibitor linagliptin, a pre-specified meta-analysis of all …
Read More »Disease Progression in Type 2 Diabetes
For the complete article, Disease Progression in Type 2 Diabetes, and information on other aspects of GLP-1 treatment, please visit Novo Nordisk’s diabetesinamerica at www.novomedlink.com/diabetes/diabetes-in-america.
Read More »CVD Risk History Predicts Gestational Diabetes
A woman’s cardiometabolic profile predicted the risk of gestational diabetes as early as seven years before pregnancy….
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.